상세 보기
Major Depressive Disorder: Rethinking and Understanding Recent Discoveries
초록
A leading goal in the field of biological psychiatry for depression is to find a promising diagnostic biomarker and selection of specific psychiatric treatment mode that is most likely to benefit patients with depression. Recent neuroimaging studies have characterized the pathophysiology of major depressive disorder (MDD) with functional and structural alterations in the neural circuitry involved in emotion or reward processing. Particularly, structural and functional magnetic resonance imaging (MRI) studies have reported that the brain structures deeply involved in emotion regulation or reward processing including the amygdala, prefrontal cortex (PFC), anterior cingulate cortex (ACC), ventral striatum, and hippocampus are key regions that provide useful information about diagnosis and treatment outcome prediction in MDD. For example, it has been consistently reported that elevated activity of the ACC is associated with better antidepressant response in patients with MDD. This chapter will discuss a growing body of evidence that suggests that diagnosis or prediction of outcome for specific treatment can be assisted by a neuroimaging-based biomarker in MDD. © 2021, Springer Nature Singapore Pte Ltd.
- 제목
- Major Depressive Disorder: Rethinking and Understanding Recent Discoveries
- 저자
- Han, Kyu-Man; Ham, Byung Joo; Kim, Yong Ku
- 발행일
- 2021-04
- ISBN
- 978-981-33-6043-3
- 언어
- ENG
- 출판사
- Kluwer Academic/Plenum Publishers
- 목차
- Part I Re-thinking Depression from a Network Perspective 1. Phenotype Network and Brain Structural Covariance Network of Major Depression - page 3 2. Task MRI-Based Functional Brain Network of Major Depression - page 19 3. White Matter-Based Structural Brain Network of Major Depression - page 35 4. The Application of a Machine Learning-Based Brain MRI Approach in Major Depression - page 57 5. Common Currency Between Experience and Brain Spatiotemporal Psychopathology of the Resting State in Depression - page 71 6. Development of Neuroimaging-Based Biomarkers in Major Depression - page 85 Part II Current Diagnostic and Neurobiological Issues 7. Challenges and Strategies for Current Classifications of Depressive Disorders Proposal for Future Diagnostic Standards - page 103 8. Epigenetics A Missing Link Between Early Life Stress and Depression - page 117 9. From Leaky Gut to Impaired Glia-Neuron Communication in Depression - page 129 10. Neurogenesis and Neuroplasticity in Major Depression Its Therapeutic Implication - page 157 11. A Load to Find Clinically Useful Biomarkers for Depression - page 175 12. Genetic Architecture of Depression Where Do We Stand Now - page 203 13. Pharmacogenetic Pharmacogenomic Tests for Treatment Prediction in Depression - page 231 14. The Role of Neurotrophic Factors in Pathophysiology of Major Depressive Disorder - page 257 Part III Current Specific Treatments for Depression 15. Clinical Application of Real-Time fMRI-Based Neurofeedback for Depression - page 275 16. Cognitive Behavioral Therapy and Mindfulness-Based Cognitive Therapy for Depressive Disorders - page 295 17. Acceptance and Commitment Therapy for Major Depressive Disorder Insights into a New Generation of Face-to-Face Treatment and Digital Self-Help Approaches - page 311 18. Current Updates on Newer Forms of Transcranial Magnetic Stimulation in Major Depression - page 333 19. Well-being Therapy in Depressive Disorders - page 351 20. Current Research on Complementary and Alternative Medicine CAM in the Treatment of Major Depressive Disorder An Evidence-Based Review - page 375 21. Psychopharmacology Algorithms for Major Depressive Disorder Current Status - page 429 Part IV Promising Future Treatments for Depression 22. Novel Psychopharmacology for Depressive Disorders - page 449 23. Creative Person-Centered Narrative Psychopharmacotherapy of Depression - page 463 24. Induced Pluripotent Stem Cells iPSCs Technology Potential Targets for Depression - page 493 25. Vaccination and Immunotherapy for Major Depression - page 503 26. Psychedelic Medicines in Major Depression Progress and Future Challenges - page 515 27. Precision Psychiatry Biomarker-Guided Tailored Therapy for Effective Treatment and Prevention in Major Depression - page 535